Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19

Author(s)
Spranger, Stefani
Thumbnail
DownloadPublished version (406.5Kb)
Publisher with Creative Commons License
Terms of use
Creative Commons Attribution NonCommercial License 4.0 https://creativecommons.org/licenses/by-nc/4.0/
Metadata
Show full item record
Abstract
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the SARS-CoV-2 virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in the epicenters of infection including Wuhan, China, Northern Italy and in the USA, the Seattle and New York City areas. The Society for Immunotherapy of Cancer (SITC) stands along with and supports our colleagues in emergency departments, intensive care units (ICUs) and inpatient wards in the global effort to overcome this unprecedented pandemic. ©2020
Date issued
2020-01
URI
https://hdl.handle.net/1721.1/124891
Department
Massachusetts Institute of Technology. Department of Biology; Koch Institute for Integrative Cancer Research at MIT
Journal
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Citation
Ascierto, Paolo Antonio, et al., "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19." Journal for ImmunoTherapy of Cancer 8, 1 (Jan. 2020): no. e000878 doi 10.1136/jitc-2020-000878 ©2020 Author(s)
Version: Final published version
ISSN
2051-1426
Collections